Biomarkers in Cancer Staging, Prognosis and Treatment Selection

Advances in genomics, proteomics and molecular pathology have generated many candidate biomarkers with potential clinical value. Their use for cancer staging and personalization of therapy at the time of diagnosis could improve patient care. However, translation from bench to bedside outside of the research setting has proved more difficult than might have been expected. Understanding how and when biomarkers can be integrated into clinical care is crucial if we want to translate the promise into reality.

[1]  B. Shapiro,et al.  Free DNA in the serum of cancer patients and the effect of therapy. , 1977, Cancer research.

[2]  F. Collins,et al.  Mutations in the p53 gene occur in diverse human tumour types , 1989, Nature.

[3]  G. Kovacs,et al.  Alteration of mitochondrial DNA in human oncocytomas , 1989, Genes, chromosomes & cancer.

[4]  The use of CA15.3 as a serum tumour marker in breast carcinoma. , 1991, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[5]  L. E. McDonald,et al.  A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[6]  C R Cantor,et al.  Immuno-PCR: very sensitive antigen detection by means of specific antibody-DNA conjugates. , 1992, Science.

[7]  M. Pike,et al.  Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. , 1994, Cancer research.

[8]  J. Herman,et al.  Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[9]  R H Hruban,et al.  Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. , 1995, The New England journal of medicine.

[10]  J. Herman,et al.  5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers , 1995, Nature Medicine.

[11]  N. Mueller.  Overview: viral agents and cancer. , 1995, Environmental health perspectives.

[12]  C. Boshoff,et al.  Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cells , 1995, Nature Medicine.

[13]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[14]  A. Levine.  p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[15]  D. Alberts,et al.  Surrogate end-point biomarkers as measures of colon cancer risk and their use in cancer chemoprevention trials. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[16]  Peter Devilee,et al.  BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients , 1997, Nature Genetics.

[17]  G. S. Johnson,et al.  An Information-Intensive Approach to the Molecular Pharmacology of Cancer , 1997, Science.

[18]  F. Révillion,et al.  ERBB2 oncogene in human breast cancer and its clinical significance. , 1998, European journal of cancer.

[19]  J N Weinstein,et al.  Fishing Expeditions , 1998, Science.

[20]  Bert Vogelstein,et al.  Somatic mutations of the mitochondrial genome in human colorectal tumours , 1998, Nature Genetics.

[21]  M. King,et al.  Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. , 1998, JAMA.

[22]  Roger Brent,et al.  Postgenomic protein analysis: The next bend in the river , 1998, Nature Biotechnology.

[23]  J. Jen,et al.  Distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma. , 1998, Journal of the National Cancer Institute.

[24]  E Gabrielson,et al.  Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[25]  R. Davis,et al.  In vivo detection and imaging of phosphatidylserine expression during programmed cell death. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[26]  J. Weinstein.  Fishing expeditions [6] , 1998 .

[27]  D. Sherer,et al.  Automated cervical cytology: meta-analyses of the performance of the PAPNET system. , 1999, Obstetrical & gynecological survey.

[28]  J. Herman,et al.  Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. , 1999, Journal of the National Cancer Institute.

[29]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[30]  J. Califano,et al.  Unknown primary head and neck squamous cell carcinoma: molecular identification of the site of origin. , 1999, Journal of the National Cancer Institute.

[31]  N. Sampas,et al.  Molecular classification of cutaneous malignant melanoma by gene expression profiling , 2000, Nature.

[32]  J. Herman,et al.  Predicting lung cancer by detecting aberrant promoter methylation in sputum. , 2000, Cancer research.

[33]  Scar,et al.  Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.

[34]  S. Groshen,et al.  Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  J. Califano,et al.  Genetic progression and clonal relationship of recurrent premalignant head and neck lesions. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  J. Weinstein.  Pharmacogenomics--teaching old drugs new tricks. , 2000, The New England journal of medicine.

[37]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[38]  E. Petricoin,et al.  Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines , 2000, Electrophoresis.

[39]  R. Elashoff,et al.  Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. , 2000, Cancer research.

[40]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[41]  J. Gray,et al.  Genome changes and gene expression in human solid tumors. , 2000, Carcinogenesis.

[42]  Regulatory issues related to marker development. , 2000, Urologic oncology.

[43]  J. Jen,et al.  Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. , 2000, Science.

[44]  S. Chevret,et al.  Virologic and immunologic parameters that predict clinical response of AIDS-associated Kaposi's sarcoma to highly active antiretroviral therapy. , 2001, The Journal of investigative dermatology.

[45]  M S Pepe,et al.  Phases of biomarker development for early detection of cancer. , 2001, Journal of the National Cancer Institute.

[46]  J. Jen,et al.  Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. , 2001, Cancer research.

[47]  N. Bianchi,et al.  Mitochondrial genome instability in human cancers. , 2001, Mutation research.

[48]  D. Sidransky,et al.  Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. , 2001, Journal of the National Cancer Institute.

[49]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[50]  C. Paweletz,et al.  New approaches to proteomic analysis of breast cancer , 2001, Proteomics.

[51]  L. Peloso,et al.  Tumor markers in breast cancer monitoring should be scheduled according to initial stage and follow-up time: a prospective study on 859 patients. , 2001, Cancer journal.

[52]  D. Botstein,et al.  Diversity of gene expression in adenocarcinoma of the lung , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[53]  Mary V. Relling,et al.  Pharmacogenetics and cancer therapy , 2001, Nature Reviews Cancer.

[54]  C. Sawyers,et al.  Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.

[55]  V. Patel,et al.  New approaches to the understanding of the molecular basis of oral cancer. , 2001, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.

[56]  Evaluation of alternative approaches for imaging cellular growth. , 2001, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[57]  C. Sotiriou,et al.  Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer , 2002, Breast Cancer Research.

[58]  P. Ravdin,et al.  Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  E. Petricoin,et al.  Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front , 2001, Oncogene.

[60]  S M Hanash,et al.  Proteomic Approaches within the NCI Early Detection Research Network for the Discovery and Identification of Cancer Biomarkers , 2001, Annals of the New York Academy of Sciences.

[61]  Frank Dudbridge,et al.  Haplotype tagging for the identification of common disease genes , 2001, Nature Genetics.

[62]  J. Herman,et al.  A gene hypermethylation profile of human cancer. , 2001, Cancer research.

[63]  C. Allis,et al.  Translating the Histone Code , 2001, Science.

[64]  E. Petricoin,et al.  Proteomics of human breast ductal carcinoma in situ. , 2002, Cancer research.

[65]  Nan Hu,et al.  2D Differential In-gel Electrophoresis for the Identification of Esophageal Scans Cell Cancer-specific Protein Markers* , 2002, Molecular & Cellular Proteomics.

[66]  S. Gutman.  Regulatory issues in tumor marker development. , 2002, Seminars in oncology.

[67]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[68]  M. Hammond,et al.  Issues and barriers to development of clinically useful tumor markers: a development pathway proposal. , 2002, Seminars in oncology.

[69]  David Botstein,et al.  Transformation of follicular lymphoma to diffuse large-cell lymphoma: Alternative patterns with increased or decreased expression of c-myc and its regulated genes , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[70]  C. Wheeler,et al.  A controlled trial of a human papillomavirus type 16 vaccine. , 2002, The New England journal of medicine.

[71]  E. Petricoin,et al.  Clinical proteomics: translating benchside promise into bedside reality , 2002, Nature Reviews Drug Discovery.

[72]  Mukesh Verma,et al.  The promise of biomarkers in cancer screening and detection. , 2002, Trends in molecular medicine.

[73]  E. Kohn,et al.  Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer , 2002, Proteomics.

[74]  Marek Kimmel,et al.  Haplotype and linkage disequilibrium architecture for human cancer-associated genes. , 2002, Genome research.

[75]  Bradley James Erickson,et al.  Computer-Aided Detection and Diagnosis at the Start of the Third Millennium , 2002, Journal of Digital Imaging.

[76]  Donald L Weaver,et al.  Revision of the American Joint Committee on Cancer staging system for breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  Ji Huang,et al.  [Serial analysis of gene expression]. , 2002, Yi chuan = Hereditas.

[78]  N. Anderson,et al.  The Human Plasma Proteome , 2002, Molecular & Cellular Proteomics.

[79]  J. Weinstein.  'Omic' and hypothesis-driven research in the molecular pharmacology of cancer. , 2002, Current opinion in pharmacology.

[80]  M. Spitz,et al.  p53 Genotypes and Haplotypes Associated With Lung Cancer Susceptibility and Ethnicity. , 2002, Journal of the National Cancer Institute.

[81]  S. Lee,et al.  Genetic polymorphisms of XRCC1 and risk of gastric cancer. , 2002, Cancer letters.

[82]  F. Sato,et al.  Application of cDNA microarrays to generate a molecular taxonomy capable of distinguishing between colon cancer and normal colon , 2002, Oncogene.

[83]  D. Sidransky,et al.  Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. , 2002, Cancer research.

[84]  David Sidransky,et al.  Emerging molecular markers of cancer , 2002, Nature Reviews Cancer.

[85]  M. Villalobos,et al.  Assessing the use of p16(INK4a) promoter gene methylation in serum for detection of bladder cancer. , 2002, European urology.

[86]  Van,et al.  A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.

[87]  J. Gray,et al.  The genetics and genomics of cancer , 2003, Nature Genetics.

[88]  A. Nakao,et al.  Molecular detection of p16 promoter methylation in the serum of recurrent colorectal cancer patients , 2003, International journal of cancer.

[89]  C. Mirkin,et al.  Nanoparticle-Based Bio-Bar Codes for the Ultrasensitive Detection of Proteins , 2003, Science.

[90]  S. Leung,et al.  Rapid clearance of plasma Epstein-Barr virus DNA after surgical treatment of nasopharyngeal carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[91]  M. Bruchez,et al.  Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots , 2003, Nature Biotechnology.

[92]  L. Kostakoglu,et al.  18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[93]  L. Sobin,et al.  TNM: evolution and relation to other prognostic factors. , 2003, Seminars in surgical oncology.

[94]  Paul Cairns,et al.  Genome-wide genetic characterization of bladder cancer: a comparison of high-density single-nucleotide polymorphism arrays and PCR-based microsatellite analysis. , 2003, Cancer research.

[95]  B. Weigl,et al.  Lab-on-a-chip for drug development. , 2003, Advanced drug delivery reviews.

[96]  E. Petricoin,et al.  Early detection: Proteomic applications for the early detection of cancer , 2003, Nature Reviews Cancer.

[97]  L. Knight,et al.  Radiopharmaceuticals for targeting the angiogenesis marker αvβ3 , 2003 .

[98]  Yingdong Zhao,et al.  Molecular Differentiation of High- and Moderate-Grade Human Prostate Cancer by cDNA Microarray Analysis , 2003, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[99]  Philip M. Long,et al.  Breast cancer classification and prognosis based on gene expression profiles from a population-based study , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[100]  K. Togashi.  Ovarian cancer: the clinical role of US, CT, and MRI , 2003, European Radiology.

[101]  Tiny Transistors Scout for Cancer , 2003, Science.

[102]  R. Rosell,et al.  Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients. , 2003, Cancer letters.

[103]  E. Lander,et al.  A molecular signature of metastasis in primary solid tumors , 2003, Nature Genetics.

[104]  R. Salunga,et al.  Gene expression profiles of human breast cancer progression , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[105]  J. Satagopan,et al.  A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment , 2003, Breast Cancer Research.

[106]  T. Fojo,et al.  Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[107]  Peter E Barker,et al.  Cancer biomarker validation: standards and process: roles for the National Institute of Standards and Technology (NIST). , 2003, Annals of the New York Academy of Sciences.

[108]  Jianfeng Xu,et al.  Polymorphisms in the CYP1A1 gene are associated with prostate cancer risk , 2003, International journal of cancer.

[109]  William C Reinhold,et al.  Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[110]  S James Adelstein,et al.  Molecular targeting with radionuclides: state of the science. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[111]  Igor L. Medintz,et al.  Self-assembled nanoscale biosensors based on quantum dot FRET donors , 2003, Nature materials.

[112]  H. Kuwano,et al.  High frequency of DAP-kinase gene promoter methylation in colorectal cancer specimens and its identification in serum. , 2003, Cancer letters.

[113]  R. Bold,et al.  Utility of tumor markers in determining resectability of pancreatic cancer. , 2003, Archives of surgery.

[114]  L. Lesko,et al.  Microarray data—the US FDA, industry and academia , 2003, Nature Biotechnology.

[115]  Caroline Seydel,et al.  Quantum Dots Get Wet , 2003, Science.

[116]  D. Mavroudis,et al.  Real-time quantification of CK-19 mRNA-positive cells in peripheral blood of breast cancer patients using the lightcycler system. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[117]  Syed Mohsin,et al.  Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer , 2003, The Lancet.

[118]  Lale Kostakoglu,et al.  Clinical role of FDG PET in evaluation of cancer patients. , 2003, Radiographics : a review publication of the Radiological Society of North America, Inc.

[119]  Peter E. Barker,et al.  Cancer Biomarker Validation: Standards and Process , 2003 .

[120]  E. Ben-Ari.  Nanoscale quantum dots hold promise for cancer applications. , 2003, Journal of the National Cancer Institute.

[121]  Michael Bittner,et al.  Gene-expression profiling in human cutaneous melanoma , 2003, Oncogene.

[122]  S. Leung,et al.  Pretherapy quantitative measurement of circulating Epstein–Barr virus DNA is predictive of posttherapy distant failure in patients with early‐stage nasopharyngeal carcinoma of undifferentiated type , 2003, Cancer.

[123]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[124]  F. Blankenberg,et al.  Feasibility of 99mTc-annexin V for repetitive detection of apoptotic tumor response to chemotherapy: an experimental study using a rat tumor model. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[125]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[126]  D. Ransohoff.  Rules of evidence for cancer molecular-marker discovery and validation , 2004, Nature Reviews Cancer.

[127]  Ruud H. Brakenhoff,et al.  Dissecting the metastatic cascade , 2004, Nature Reviews Cancer.

[128]  K. Pantel,et al.  Bone marrow micrometastases and circulating tumor cells: current aspects and future perspectives , 2004, Breast Cancer Research.

[129]  K. Awai,et al.  Pulmonary nodules at chest CT: effect of computer-aided diagnosis on radiologists' detection performance. , 2004, Radiology.

[130]  Nirag Jhala,et al.  Diagnostic Markers That Distinguish Colon and Ovarian Adenocarcinomas: Identification by Genomic, Proteomic, and Tissue Array Profiling , 2004 .

[131]  S. Nelson,et al.  DNA-microarray analysis of brain cancer: molecular classification for therapy , 2004, Nature Reviews Neuroscience.

[132]  S. Bates,et al.  A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. , 2004, Current pharmaceutical design.

[133]  G. Bepler,et al.  Ribonucleotide Reductase Messenger RNA Expression and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients , 2004, Clinical Cancer Research.

[134]  Claire Holloway,et al.  Enumeration of Circulating Tumor Cells in the Blood of Breast Cancer Patients After Filtration Enrichment: Correlation with Disease Stage , 2004, Breast Cancer Research and Treatment.

[135]  Tanja Fehm,et al.  Circulating Tumor Cells in Patients with Breast Cancer Dormancy , 2004, Clinical Cancer Research.

[136]  Margarita L Zuley,et al.  Can computer-aided detection with double reading of screening mammograms help decrease the false-negative rate? Initial experience. , 2004, Radiology.

[137]  H. Lenz.  The use and development of germline polymorphisms in clinical oncology. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[138]  David C Christiani,et al.  High-resolution single-nucleotide polymorphism array and clustering analysis of loss of heterozygosity in human lung cancer cell lines , 2004, Oncogene.

[139]  Gangning Liang,et al.  Preferential response of cancer cells to zebularine. , 2004, Cancer cell.

[140]  M. Fukuoka,et al.  Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer. , 2004, Lung cancer.

[141]  S. Bates,et al.  T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. , 2004, Blood.

[142]  Manel Esteller,et al.  DNA methylation and cancer therapy: new developments and expectations , 2005, Current opinion in oncology.

[143]  M. Meyerson,et al.  EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.

[144]  F. Hoek,et al.  The usefulness of CA15.3, mucin-like carcinoma-associated antigen and carcinoembryonic antigen in determining the clinical course in patients with metastatic breast cancer , 1995, Journal of Cancer Research and Clinical Oncology.

[145]  Jason A. Papin,et al.  Reconstruction of cellular signalling networks and analysis of their properties , 2005, Nature Reviews Molecular Cell Biology.